Senseonics Holdings, Inc. - 10-Q Summary (Q3 2024)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Senseonics Holdings, Inc. is a medical technology company developing long-term, implantable continuous glucose monitoring (CGM) systems, primarily the Eversense platform. The company operates in a single segment focused on diabetes products and services. A key development in the period was the FDA 510(k) clearance of the Eversense 365 system in September 2024, marking a transition from the previous Eversense E3 (180-day) product.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $4.3 million | $6.1 million | $14.2 million | $14.4 million |
| Gross Profit (Loss) | ($4.1) million | $1.2 million | ($3.4) million | $2.0 million |
| Gross Margin | (95.0%) | 19.2% | (24.1%) | 13.9% |
| Operating Loss | ($22.8) million | ($19.0) million | ($60.6) million | ($58.6) million |
| Net Loss | ($24.0) million | ($24.1) million | ($63.1) million | ($43.2) million |
| Cash & Equivalents | $27.1 million | (Balance Sheet Data) | ||
| Short-term Investments | $47.4 million | (Balance Sheet Data) | ||
| Total Liquidity | $74.5 million | (Unrestricted Cash + Investments) | ||
| Total Debt (Carrying Value) | $53.8 million | (Current + Long-term) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 30% in Q3 2024 compared to Q3 2023. This was driven by a planned winddown of Eversense E3 inventory to prepare for the Eversense 365 launch. Related party revenue (Ascensia) dropped significantly from $5.7M to $3.3M.
- Gross Margin Deterioration: The company reported a gross loss of $4.1M in Q3 2024, compared to a profit of $1.2M in the prior year. This was primarily due to $4.8 million in one-time charges related to inventory write-offs and supplier prepayment impairments during the transition from Eversense E3 to Eversense 365.
- Expense Management: R&D expenses decreased by $2.3M quarter-over-quarter due to the completion of clinical trials for the 365-day system. SG&A expenses increased slightly by $0.8M due to higher personnel and consultant costs.
- Debt Structure: The company drew down the Tranche 2 Loan of $10.0M in January 2024. Total debt carrying value increased due to this new funding and accretion of fees.
Outlook, Risks, and Contingencies
- Going Concern Warning: Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern for the 12-month period following the issuance of these financial statements. The company expects existing cash ($74.5M) to be insufficient to fund operations and meet debt covenants through Q3 2025 without additional funding.
- Product Launch: Commercialization of the Eversense 365 system began in the U.S. in Q4 2024 following FDA clearance in September 2024. The company is transitioning its inventory and sales focus to this new 365-day product.
- Subsequent Financing: On October 24, 2024, the company entered into a registered direct offering and private placement of warrants, raising approximately $15.0 million in net proceeds (after fees) to bolster liquidity.
- Legal Proceedings: The company is defending against a patent infringement lawsuit filed in May 2024 by Cellspin Soft, Inc. The validity of the asserted patents is currently being challenged in Inter Partes Review proceedings.
- Customer Concentration: The company remains highly dependent on Ascensia, which accounted for 84% of total revenue for the nine months ended September 30, 2024.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $15M raised in October 2024 combined with existing cash to meet the minimum cash covenants of the Hercules Loan and Security Agreement.
- Inventory Transition: Confirm the extent of remaining Eversense E3 inventory write-offs and the ramp-up rate of Eversense 365 sales to ensure gross margins recover from the one-time charges.
- Debt Covenants: Monitor compliance with the performance covenant requiring net product revenue on a trailing six-month basis, which commenced July 1, 2024.
- Legal Exposure: Track the outcome of the Cellspin Soft patent litigation and the Inter Partes Review proceedings.
- Revenue Mix: Assess the sustainability of revenue given the 84% concentration with Ascensia and the impact of the product transition on sales projections.